Peptidia vs PepPedia in 2026: evidence interface or all-in-one toolkit?

Feature grids can hide the most important product choice. Peptidia asks, “Can the reader inspect the evidence behind this conclusion?” PepPedia’s public description asks a broader question: “Can one app combine a reference library with the tools a peptide-curious user may want around it?”

Neither question is universally superior. But they lead to different designs, and readers should choose based on the failure mode they most want to avoid.

Peptidia’s Evidence Passport makes evidence maturity, source type, missing links, and review date first-class content. A negative human trial is not buried below a positive animal finding, and a mechanistic hypothesis is not presented as a clinical outcome.

Peptidia also keeps your own records in a private Lab: products, the amounts you enter, routes, sites, a journal, trends, and vials. New Lab records are encrypted on your iPhone and never sent to Peptidia’s servers. Peptidia never suggests an amount to take or generates a protocol. Its library and the Peptarch never give doses, and it recommends no vendor.

PepPedia’s current App Store description highlights a broad library, citations, a research section, personal journaling, inventory, metrics, and math tools, and it says your data syncs across devices. A reader who values consolidation may prefer that surface.

When evaluating breadth, examine each evidence claim independently. The presence of many supporting features does not by itself indicate the strength of a study, and a citation count does not substitute for source quality or applicability.

Open the same peptide in both products and look for the strongest disconfirming evidence, not the most exciting claim. Ask whether you can identify the study population, evidence type, limitations, and editorial review date. Then compare the personal tools you will actually use. That test is more informative than selecting whichever product advertises the longest list.